"Half-Life" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity.
| Descriptor ID |
D006207
|
| MeSH Number(s) |
G01.910.405
|
| Concept/Terms |
Half-Life- Half-Life
- Half Life
- Half-Lifes
- Halflife
- Halflifes
|
Below are MeSH descriptors whose meaning is more general than "Half-Life".
Below are MeSH descriptors whose meaning is more specific than "Half-Life".
This graph shows the total number of publications written about "Half-Life" by people in this website by year, and whether "Half-Life" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 3 | 3 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 3 | 3 |
| 2018 | 0 | 2 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 3 | 3 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Half-Life" by people in Profiles.
-
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. N Engl J Med. 2023 02 23; 388(8):694-705.
-
An update of the current pharmacotherapeutic armamentarium for hemophilia A. Expert Opin Pharmacother. 2022 Jan; 23(1):129-138.
-
Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B. Haemophilia. 2021 Jul; 27(4):574-580.
-
The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021 02 13; 397(10274):630-640.
-
Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. Sci Rep. 2020 08 03; 10(1):13031.
-
Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting. Haemophilia. 2019 Mar; 25(2):213-220.
-
Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII. Haemophilia. 2018 May; 24(3):376-384.
-
Defining extended half-life rFVIII-A critical review of the evidence. Haemophilia. 2018 May; 24(3):348-358.
-
Extended half-life clotting factor concentrates: results from published clinical trials. Haemophilia. 2016 Jul; 22 Suppl 5:25-30.
-
Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery. Haemophilia. 2016 Jul; 22(4):e259-66.